Bissan Al‐Lazikani

The University of Texas MD Anderson Cancer Center

Full Professor(heuristic)

Computational Drug Discovery Methods · Computational Theory and Mathematics

h-index42

i10-index68

Publications314

Citations19,602

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 95

Supplementary Table 10 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Table 3 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Table 1 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Table 7 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Table 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026-06-17
Supplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
2026-06-17
Supplementary Figure 8 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026-06-17
Supplementary Figure 10 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026-06-17
Supplementary Table 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026-06-17
Supplementary Figure 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026-06-17
Supplemental Figure S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
2026-06-17
Supplementary Figure 9 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026-06-17
Supplementary Figure S2 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Figure S11 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Figure S9 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Figure S12 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplemental Figure S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
2026-06-17
Supplementary Table 5 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Figure S5 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17
Supplementary Figure S6 from Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States
2026-06-17

Open author page on OpenAlex →